Juvéderm, Restylane, RHA, Belotero, Revanesse, Obagi saypha, and Evolysse offer different hyaluronic acid filler options. But choosing a brand is only part of choosing a treatment.
Each collection contains products with particular properties and approved uses. The right question is which specific product suits your anatomy and the change you want to achieve.
What these fillers have in common
These collections contain hyaluronic acid, or HA, gels. HA attracts water, while the manufactured gel provides physical volume and support within selected tissues.
Products can differ in softness, elasticity, cohesivity, swelling behavior, and other characteristics. Sharing the same main ingredient does not make them interchangeable.
Juvéderm
The Juvéderm collection includes products for selected facial folds, lip enhancement, and contour or volume changes.
Approval for one product and treatment area does not apply automatically to the entire collection.
Skinvive is also part of the Juvéderm portfolio. Its approved uses include improving cheek skin smoothness and reducing neck lines in adults over age 21. These purposes differ from adding projection or facial contour.
Restylane
Restylane includes multiple HA formulations with different tissue-support and movement characteristics.
Some products provide structural support, while others prioritize flexibility or more delicate correction. Your provider should identify the exact product and explain why its properties suit the proposed area.
RHA Collection
RHA stands for resilient hyaluronic acid. The collection contains products with differing characteristics for particular treatment purposes.
Its emphasis on adapting to facial movement does not mean every RHA product suits every mobile area. Natural-looking results depend on appropriate selection, placement, and amount.
Belotero
Belotero products use a distinct gel-manufacturing approach and have product-specific indications.
The US collection expanded in July 2026 with FDA approval of Belotero Intense (+) Lidocaine for lip augmentation in adults over age 21.
Revanesse
Revanesse includes HA products such as Versa+ and Lips+, with different approved indications.
As with other collections, the specific formulation should guide the discussion. A product intended for facial folds should not automatically be treated as interchangeable with one selected for lip augmentation.
Obagi saypha
Obagi Medical’s saypha collection is a newer addition to the US filler market.
Saypha MagIQ received FDA approval in September 2025 for correcting moderate to severe facial wrinkles and folds, such as nasolabial folds.
Saypha ChIQ received FDA approval in June 2026 for cheek augmentation and restoration of midface volume deficits. Both indications apply to adults over age 21.
Evolysse
Evolysse Form and Evolysse Smooth received FDA approval in February 2025 for correcting moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds, in adults age 22 and older.
Manufactured by Symatese and commercialized in the United States by Evolus, these products provide additional HA gel options. Their formulations differ, and selection should reflect the intended correction.
Does newer mean better?
A newer product may offer useful formulation characteristics or additional treatment options. It does not automatically outperform established products for every concern.
Your anatomy, tissue quality, existing filler, desired change, and treatment history all influence selection. Injection depth and the amount used matter as well.
All fillers carry risks, including swelling, bruising, infection, and uncommon but serious vascular complications. HA filler may be treated with hyaluronidase when appropriate, but reversal is not always simple or complete.
Choosing treatment at Modern Aesthetics
At Modern Aesthetics in San Jose, I use Juvéderm and RHA products as part of individualized treatment plans. Other brands are included here for education; their inclusion does not mean every product is offered at the practice.
Schedule a consultation to discuss the product, anticipated improvement, risks, maintenance, and total cost appropriate for your goals.
Updated October 23, 2026.